Key result
Selective use of drug-eluting stents was an independent predictor of freedom from major adverse cardiac events at 12 months (OR 0.68; 95% CI 0.56-0.81).
Observational (n=9,204)
Yes
Odds Ratio: 0.68 (95% CI 0.56–0.81)
Despite a steady decline in DES use and an increasing patient risk profile between 2004 and 2008, procedural success remained high and 12-month adverse outcomes remained low in Australian PCI practice.
No takes yet. Share an insight, caveat, or question.
Supports selective DES in real-world PCI; hypothesis-generating and should not yet change practice without RCTs.
Yan et al. (2011) conducted an observational in Percutaneous coronary intervention (n=9,204). Selective use of drug-eluting stents (DES) was evaluated on Freedom from composite major adverse cardiac events (MACE) at 12 months (OR 0.68, 95% CI 0.56-0.81). Selective use of drug-eluting stents was an independent predictor of freedom from major adverse cardiac events at 12 months (OR 0.68; 95% CI 0.56-0.81).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: